Oncorena

Executive Summary

Oncorena is a Swedish biopharmaceutical company developing orellanine, a novel fungal toxin-based therapy for metastatic renal cell carcinoma (RCC). The compound is derived from the mushroom Cortinarius orellanus and selectively targets cancer cells through inhibition of protein synthesis. Oncorena is currently conducting a Phase 1/2 clinical trial evaluating orellanine in patients with metastatic clear-cell or papillary RCC, with a focus on safety, tolerability, and preliminary anti-tumor efficacy. RCC is a common and aggressive cancer with high unmet need, especially after frontline therapies fail. Orellanine's unique mechanism may offer a new option for patients who have progressed on standard treatments. The company is privately held and based in Uppsala, Sweden, and has been operating since 2011. Early clinical data, if positive, could position Oncorena as a significant player in the renal cancer space and attract partnership or licensing interest from larger oncology-focused pharmaceutical companies.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 interim safety and efficacy data readout60% success
• Q4 2026Initiation of dose expansion cohort75% success
• Q1 2027Potential orphan drug designation or fast track from FDA50% success